glp-1 obesity drug news october 2025 today GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 The Obesity-Drug Revolution Is Stalling

98,147 users of GLP1-RA and 2,488,303 users of DPP-4i were followed up with the median follow-up among users of GLP1-RA ranging from 1.8 to 3.0 years

Recent LegitScript data reveals the skyrocketing promotion of both GLP-1 medications and reported ads associated with selling compounded GLP-1 medications (press release)

However, the impact of reduced carotid intimamedia thickness on reduction of CV events has not been elucidated

Saxenda (liraglutide) Saxenda (liraglutide) is FDA-approved for chronic weight management

"All the clinical trials that showed these medications working also included education on eating and exercise

HbA1c: Four studies (200 participants) reported changes in HbA1c of which due to lack of common comparator, only two studies could be pooled (Electronic Supplementary Fig